There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…
Our good friends at Drug Delivery Technology have, as of January, changed the name of their publication to Drug Development and Delivery. Why is this significant? We think that drug…
BioPharm Int'l recently published a nice overview of where the FDA debate is on biosimilars. Highlights: There is broad support for legislation which clarifies the path for biosimilars to be…
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
A former business development colleague of mine used to refer to some prospects as having "champagne tastes with beer wallets." His meaning was clear. It's one thing to want champagne,…
Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes. I leave it to the powers that be…
It is regrettable that the FDA issued a complete response letter to Jazz Pharmaceuticals for JZP-6. If there is a disease that can use some innovation, it's fibromyalgia. The CRL…
Drug delivery is not dead! In fact, drug delivery can ba a valuable tool for developing and commercializing drugs faster and at lower cost versus NCEs.
Late last month, Johnson and Johnson (J&J) announced the results of Phase III clinical trials comparing tapentadol extended release compared to oxycodone controlled release and placebo. In this study, J&J…